News
AOP Orphan Pharmaceuticals AG, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia
13. 5. 2019AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV)
21. 2. 2019AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
17. 12. 2018
Meet Us Globally
- 22Sep.
International Congress of Parkinson's Disease and Movement Disorders
NICE, FRANCE - 5Nov.
CPhI
Frankfurt, Germany - 11Nov.
Bio-Europe
Hamburg, Germany
Meet Us in Germany
- 9Oct.
Deutscher Schmerzkongress
Frankfurt - 11Oct.
Annual Conference DGHO
BERLIN, GERMANY - 11Oct.
Experts Press Conference
at DGHOBERLIN, GERMANY
From the Concept to the Drug
AOP Orphan headquarters team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Orphan headquarters using the link below.